Mass tort marketing often moves fast. When a new litigation opportunity gains momentum, plaintiff firms need timely visibility, clear messaging, and intake pathways that can convert qualified claimants before competitors dominate the conversation. But...
Social media harm litigation is moving from a novel theory to a serious plaintiff-side practice area. The legal theory is no longer limited to harmful posts or third-party content. Increasingly, plaintiffs are focusing on platform design itself: recommendation...
Depo-Provera claims are quickly becoming a campaign category that plaintiff firms should monitor closely. The litigation centers on allegations that long-term use of Depo-Provera, a contraceptive injection containing medroxyprogesterone acetate,...
For mass tort and plaintiff firms, case acquisition is not just a marketing expense. It is a pipeline investment. Every paid lead source, referral partner, call campaign, co-counsel relationship, and digital intake channel should be evaluated by the same core...
The U.S. Judicial Panel on Multidistrict Litigation has created a new MDL for Boston Scientific spinal cord stimulator products liability cases, but the order is narrower than some plaintiffs requested. In MDL No. 3181, the Panel centralized Boston...
PFAS litigation continues to evolve quickly, and recent EPA actions are giving attorneys new regulatory benchmarks to evaluate water contamination claims. For law firms handling toxic exposure, environmental contamination, municipal water, or mass tort matters, the...